Dr. Shook has received consulting fees, speaking fees, and/or honoraria (less than $10,000) from Abbott Immunology.
Systemic Lupus Erythematosus Clinical Studies
Progression of carotid intima-media thickness and plaque in women with systemic lupus erythematosus
Article first published online: 29 FEB 2008
Copyright © 2008 by the American College of Rheumatology
Arthritis & Rheumatism
Volume 58, Issue 3, pages 835–842, March 2008
How to Cite
Thompson, T., Sutton-Tyrrell, K., Wildman, R. P., Kao, A., Fitzgerald, S. G., Shook, B., Tracy, R. P., Kuller, L. H., Brockwell, S. and Manzi, S. (2008), Progression of carotid intima-media thickness and plaque in women with systemic lupus erythematosus. Arthritis & Rheumatism, 58: 835–842. doi: 10.1002/art.23196
- Issue published online: 29 FEB 2008
- Article first published online: 29 FEB 2008
- Manuscript Accepted: 5 NOV 2007
- Manuscript Received: 6 FEB 2007
- NIH. Grant Numbers: R01-AR-46588-05, R01-AR-002213-05
- NIH (National Heart, Lung, and Blood Institute). Grant Number: R01-HL-077449
Women with systemic lupus erythematosus (SLE) are at high risk of cardiovascular disease (CVD). The goals of this study were to determine the extent of atherosclerotic progression among women with SLE compared with a group of healthy controls and to determine whether factors attributed to SLE or its treatment were associated with atherosclerotic progression independent of traditional CVD risk factors.
A longitudinal study of women with SLE from the Pittsburgh Lupus Registry was conducted. Women 18 years of age and older (n = 217) underwent carotid ultrasound at baseline and at followup, an average of 4.19 years later. Clinical, serologic, and SLE-related factors, and disease treatment were evaluated. Outcomes were changes in carotid intima-media thickness (IMT) and plaque. Progression of CVD in a sample of women without lupus was used for comparison.
The patients' mean ± SD age at baseline was 45.1 ± 10.3 years, and the mean ± SD IMT progression rate was 0.011 ± 0.03 mm per year. After controlling for traditional CVD risk factors, higher serum creatinine levels were associated with IMT progression (P = 0.0006). Plaque prevalence was 31% at baseline and 40% at followup; plaque progression occurred in 27% of the patients. Higher serum C3 levels and immunosuppressant use at baseline were related to plaque progression (P = 0.04 and P = 0.02, respectively) independent of traditional CVD risk factors. The plaque progression rate was higher than, and the IMT progression rate was similar to, those in the control group.
SLE patients have accelerated plaque progression compared with controls. SLE-related risk factors are associated with the progression of IMT and plaque after controlling for traditional CVD risk factors. Carotid B-mode ultrasound may serve as a surrogate end point in SLE intervention trials and clinically to track SLE management.